


ABSTRACT

5 The invention relates to novel compounds having formula
(I)



(I)

10 wherein Cy, X, Y, L and R₁₋₆ are as defined herein. The
compounds bind CD11/CD18 adhesion receptors such as
Lymphocyte Function-associated Antigen-1 (LFA-1) and are
therefore useful for treating disorders mediated by LFA-
1 such as inflammation and autoimmune diseases.